6 results about "Sunitinib" patented technology

The invention discloses an application of sunitinib in preparation of a medicine for treating secondary injury caused by intracranial hemorrhage. It is found for the first time that sunitinib can act on a CSF-1R / PI3K / Akt axis, pathological activation and pro-inflammatory response of microglial cells are effectively inhibited, the normal phagocytic function and lipid metabolism balance of the microglial cells are remarkably recovered, myelin sheath damage around hematoma is effectively relieved, and the neurological function score, the movement coordination ability and the exploration behavior of ICH mice are remarkably improved; the progress of secondary injury caused by intracranial hemorrhage is hindered from multiple dimensions, the curative effect is superior to that of a positive control drug pecetinib (PLX3397), and a brand new molecular target and an interference strategy are provided for comprehensive treatment of ICH.

Methods and materials for treating or preventing cardiotoxicity and / or hypertension induced by one or more anti-cancer agents (e.g., tyrosine kinase inhibitor (TKI) -induced cardiotoxicity (e.g., sunitinib-induced cardiotoxicity) and / or TKI-induced hypertension (e.g., sunitinib-induced hypertension)) are provided herein. For example, provided herein are methods for using polypeptides (e.g., chimeric polypeptides) that include (a) one or more natriuretic peptides and (b) one or more angiotensin 1-7 (ANG1-7) polypeptides to treat or prevent cardiotoxicity and / or hypertension induced by one or more anti-cancer agents.

The present application belongs to the technical field of biological medicine, and relates to a gene therapy preparation for treating drug-resistant renal cell carcinoma as well as a preparation method and application thereof. It is found for the first time that UBL3 is a key gene for mediating cross-resistance of VEGFR inhibitors of renal cancer, and a lipid nanoparticle composite system integrating specific gene editing and active targeted delivery functions is constructed based on this. The preparation can effectively restore the sensitivity of drug-resistant tumors to first-line drugs such as sunitinib, and shows a significant anticancer effect in in-vivo and in-vitro models, and has important clinical transformation value.

The invention relates to a gas chromatography detection method for the residual quantity of 2-chloropyrrole in a sunitinib intermediate 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid, and belongs to the technical field of detection. An electron capture detector is adopted, an antioxidant is added in a headspace sampling mode, the oxidation problem of a sample is avoided, and the trace 2-chloropyrrole is detected. The method is sensitive, accurate, good in repeatability, low in instrument operation cost, simple and rapid in detection process and capable of better controlling the 2-chloropyrrole residual quantity in the production of the sunitinib intermediate 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid.

Selective and potent inhibitors of G protein-coupled receptor kinase 5 (GRK5), a pharmaceutical composition comprising same, and a method of use, such as in the treatment of heart disease or cancer.

The present application relates to a kind of cell membrane-coated pH-responsive nanogel and its preparation method, the pH-responsive nanogel is that chitosan is crosslinked by crosslinking agent to form nanogel, then load polypeptide ENO1, and further load drug sunitinib, finally, it is prepared by coating kidney cancer cell membrane.The pH-responsive nanogel prepared in the present application as the carrier of polypeptide and drug, with the advantages of good biocompatibility, high drug loading rate, etc., in the tumor microenvironment response dissociation release drug, real-time monitoring is carried out to focus area during treatment.